Missouri University of Science and Technology

Scholars' Mine
Electrical and Computer Engineering Faculty
Research & Creative Works

Electrical and Computer Engineering

01 Feb 2018

CAMKs Support Development of Acute Myeloid Leukemia
Xunlei Kang
Jie Huang
Missouri University of Science and Technology, jieh@mst.edu

Follow this and additional works at: https://scholarsmine.mst.edu/ele_comeng_facwork
Part of the Electrical and Computer Engineering Commons

Recommended Citation
X. Kang and J. Huang, "CAMKs Support Development of Acute Myeloid Leukemia," Journal of Hematology
and Oncology, vol. 11, no. 1, BioMed Central, Feb 2018.
The definitive version is available at https://doi.org/10.1186/s13045-018-0574-8

This work is licensed under a Creative Commons Attribution 4.0 License.
This Article - Journal is brought to you for free and open access by Scholars' Mine. It has been accepted for
inclusion in Electrical and Computer Engineering Faculty Research & Creative Works by an authorized administrator
of Scholars' Mine. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for
redistribution requires the permission of the copyright holder. For more information, please contact
scholarsmine@mst.edu.

Kang et al. Journal of Hematology & Oncology (2018) 11:30
https://doi.org/10.1186/s13045-018-0574-8

RESEARCH

Open Access

CAMKs support development of acute
myeloid leukemia
Xunlei Kang1,2*† , Changhao Cui1,4†, Chen Wang2,3, Guojin Wu1, Heyu Chen1, Zhigang Lu1, Xiaoli Chen1, Li Wang4,
Jie Huang5, Huimin Geng6, Meng Zhao3, Zhengshan Chen7, Markus Müschen7, Huan-You Wang8
and Cheng Cheng Zhang1*

Abstract
Background: We recently identified the human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse
ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls). We also demonstrated
that PirB is important for the development of acute myeloid leukemia (AML), but exactly how an inhibitory receptor such
as PirB can support cancer development is intriguing.
Results: Here, we showed that the activation of Ca (2+)/calmodulin-dependent protein kinases (CAMKs) is coupled with
PirB signaling in AML cells. High expression of CAMKs is associated with a poor overall survival probability in patients with
AML. Knockdown of CAMKI or CAMKIV decreased human acute leukemia development in vitro and in vivo. Mouse AML
cells that are defective in PirB signaling had decreased activation of CAMKs, and the forced expression of CAMK partially
rescued the PirB-defective phenotype in the MLL-AF9 AML mouse model. The inhibition of CAMK kinase activity or
deletion of CAMKIV significantly slowed AML development and decreased the AML stem cell activity. We also found that
CAMKIV acts through the phosphorylation of one of its well-known target (CREB) in AML cells.
Conclusion: CAMKs are essential for the growth of human and mouse AML. The inhibition of CAMK signaling may
become an effective strategy for treating leukemia.
Keywords: Acute myeloid leukemia, CAMK, PirB, LILRB2, CREB, Leukemic stem cell

Background
Recently, we identified the human leukocyte
immunoglobulin-like receptor B2 (LILRB2) and its
mouse ortholog-paired Ig-like receptor (PirB) as receptors for several angiopoietin-like proteins (Angptls) [1].
LILRB2 and PirB are expressed by hematopoietic stem
cells (HSCs) and leukemia stem cells in humans and
mice, respectively, and support the ex vivo expansion of
HSCs and acute myeloid leukemia (AML) development
[1, 2]. The level of LILRB2 mRNA is significantly higher
in human acute monoblastic and monocytic leukemia
cells (M5 subtype of AML) than in other AML cells [1].
A deficiency of PirB in the MLL-AF9 and AML1-ETO9a
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AML mouse models resulted in increased differentiation
and decreased self-renewal of leukemia stem cells and
significantly downregulated expression of a large number
of tumor-promoting genes [1]. Although it was known
that PirB inhibits the differentiation of myeloid-derived
suppressive cells to stimulate solid cancer development
[3], our results indicate that certain immune inhibitory
receptors can be expressed on cancer stem cells and play
essential roles in inhibiting differentiation and supporting
self-renewal of these cells.
LILRB2 contains four extracellular Ig-like domains
and a cytoplasmic portion with three immunoreceptor
tyrosine-based switch motifs (ITIMs) [4]. The mouse
ortholog PirB has six extracellular Ig-like domains and
four ITIMs in its intracellular domain. The LILRB2/PirB
ITIMs recruit tyrosine phosphatases SHP-1 and SHP-2
[5–7]. We were intrigued as to how inhibitory receptors
such as LILRB2 and PirB support stem cell activity and
cancer development. We found that binding of Angptls
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to PirB/LILRB2 induces activation of tyrosine phosphatase SHP-1/SHP-2 and calcium/calmodulin-dependent
protein kinase CAMKIV [1], both known to be critical for
HSC repopulation and stimulation of leukemia development
[1, 2, 8–10]. We also found that SHP can induce CAMK
activation in AML cells [1, 11].
CAMKs are serine/threonine kinases that are activated
by increases of intracellular calcium concentration and
that mediate subsequent cellular activities. Few studies have
shown that CAMKs play important roles in hematopoietic
physiology and pathology. CAMKIV is required for HSC
activity; camk4-knockout mice have defects in HSC survival
and proliferation [10]. CAMKII suppresses differentiation
and stimulates proliferation of myeloid leukemia cells [9].
CREB is one of the well-known targets of CAMKs in
hematopoietic cells, which can be phosphorylated and activated by CAMKs. This signaling plays a critical role in both
normal hematopoiesis and leukemogenesis [11–13].
In this study, we sought to investigate the function of
CAMKs in AML cells and understand how CAMKs support PirB signaling in AML development. We found that
the expression of several CAMKs inversely correlates with
the overall survival of human AML patients. Knockdown
of CAMKs decreased human myeloid leukemia development in vitro and in vivo. In the mouse MLL-AF9 primary
AML cells, the defective PirB signaling decreased CAMK
activation, and the forced expression of CAMKs partially
rescued the PirB-defective phenotype. Importantly, the
inhibition of CAMK kinase activity or deletion of CAMKIV
significantly lowered the activity of AML stem cells. By
rescue assay, we also identified the phosphorylation of
CREB is critical downstream for CAMKIV signaling in
AML cells. Our results indicate that the CAMK signaling
supports self-renewal and inhibits apoptosis of AML cells.

Methods
Mice

C57 BL/6 and NOD/SCID-IL2RG (NSG) mice were purchased from the UT Southwestern Medical Center animal
breeding core facility or Jackson Labs. The PirB TM mice
[14] and CaMKIV-null mice [10] were purchased from
MMRRC and Jackson Labs, respectively. Mice were maintained at the UT Southwestern Medical Center animal
facility. All animal experiments were performed with the
approval of UT Southwestern Committee on Animal Care
and University of Missouri Committee on Animal Care.
Antibodies, reagents, and PCR primers

Antibodies for flow cytometry, anti-Kit-APC, anti-Mac1-APC, anti-Gr-1-PE, anti-CD3-APC, and anti-B220-PE,
were purchased from BioLegend and used as described
[1]. The manufacturers and catalog numbers for other
antibodies and reagents are as follows: anti-PirB-PE, R&D
Systems, FAB2754P; pCAMKI, Santa Cruz, sc-28438;
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anti-pCAMKII, Abcam, ab32678; anti-pCAMKIV, Santa
Cruz Biotechnology, sc-28443-R; anti-CAMKI, Abcam,
ab68234; anti-CAMKII, Cell Signaling, 4436; antiCAMKIV, Cell Signaling, 4032; anti-pCREB, Cell Signaling, 9198S; anti-CREB, Cell Signaling, 9197S; anti-actin,
Sigma Aldrich, A2066; STO-609, Sigma Aldrich, S1318;
KN93, Sigma Aldrich, K1385; The PCR primer sequences
were as follows: hCAMKI forward: CGGAGGACA TTAG
AGACA, reverse: CTCGTCATAGAAGGGAGG-3; hCAM
KIV forward: GATGAAAGAGGCGATCAG, reverse:
TAGGCCCTCCTCTAGTTC. PirB forward: GAG AAT
CACCAGACACATGC, PirB reverse: CTGCCCTCATG
TCTTAACTT, mCAMKIV forward: AAGCAGGCGG
AAGACATTAGG, CAMKIV reverse: AGTTTCTGAG
TCCTCTTGTCCT.
Virus infection and leukemia cell transplantation

For retrovirus production, human embryonic kidney
293T cells were grown in DMEM with 10% fetal bovine
serum (FBS) and transfected by MSCV-MLL-AF9-IRESYFP, MSCV-CAMKIV-IRES-GFP, MSCV-CAMKI-IRESGFP, or MSCV-CREB-IRES-GFP encoding plasmids and
pCL-ECO to produce retroviruses. The infection of
Linage-negative cells with retrovirus was performed as
described previously [1, 15, 16]. Briefly, we infected Lin−
cells with retroviral supernatant in the presence of 8 μg/mL
polybrene. After infection, these cells were incubated overnight in medium with 10% FBS, 20 ng/mL SCF, 10 ng/mL
IL-3, and 10 ng/mL IL-6. Infected cells (300,000) were
transplanted into lethally irradiated (1000 rad) WT mice by
retro-orbital injection. For secondary transplantation, YFP+
bone marrow (BM) cells from primary transplanted mice
were sorted and transplanted into mice with 200,000
normal BM cells as competitors.
For lentivirus production, the lentiviral vector Pll3.7 was
used to express shRNAs to target CAMKI (sense: TGCCAGAGAATCTGCTGTACTATTCAAGAGATAGTA CAGC
AGATTCTCTGGCTTTTTTC; antisense: GAAAAAAGC
CAGAGAATC TGCTGTACTATCTCTTGAATAGTACA
GCAGATTCTCTGGCA) and CAMKIV (sense: TGATAT
TACAGTGAGCGAGATGTTCAAGAGACATCTCGCTC
ACTGTAATATCTTTTTTGGAAC; antisense: TCGAGT
TCCAAAAAAGATATTACAGTGAGCGAGATGTCTC
TTGAACATCTCGCTCACTGTAATATCA). The lentivirus plasmid, pSPAX2, and pMD2.G (4:3:1) were transfected using PolyJet™ In Vitro DNA Transfection Reagent
(SignaGen Laboratories) into 293T cells. The resulting virus
supernatant was collected 48–72 h later.
For Crisper-Cas9 system, we used pCW-Cas9 (gift from
Eric Lander & David Sabatini (Addgene plasmid # 50661)
[17]) to make stable MV4-11-Cas9 cell line, and designed
three gRNA targeting the CAMK1 (gRNA1-GCTAC
GACTTCCGAGATGTTC; gRNA2-GGAGCTCTTTGA
CCGTATTGG; gRNA3-GATCCCGGTGTACAATGCCC)
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and one scramble gRNA (GAACGACTAGTTAGGC
GTGTA).
Flow cytometry, immunohistochemistry, and cytospin
assays

We performed flow cytometry, immunohistochemistry,
and cytospin as described previously [1, 15, 16]. For flow
cytometry analysis of AML cells, peripheral blood or BM
cells were stained with anti-Mac-1-APC, anti-Gr-1-PE,
anti-CD3-APC, anti-B220-PE, or anti-Kit-PE monoclonal
antibodies (BioLegend). For analysis of apoptosis, indicated
AML cells were stained with PE-conjugated anti-annexin V
and 7-AAD (BD Pharmingen) according to the manufacturer’s instructions.
Human AML mouse xenograft model

Human leukemia cell lines were cultured in RPMI supplemented with 10% FBS at 37 °C in 5% CO2 and the normal
level of O2. Human leukemia cell lines were from ATCC.
Xenografts were performed essentially as we described
[11, 18]. Briefly, adult NSG mice (6–8 weeks old) were
sub-lethally irradiated with 250 cGy total body irradiation
prior to transplantation. ShRNA-infected cells were resuspended in 200 μl PBS containing 1% FBS at a final dose of
1 × 106 human GFP+ viable cells per mouse for retroorbital injection. One to 4 months after transplantation,
the peripheral blood (PB), BM, spleen, and liver were
assessed for engraftment by flow cytometry.
CFU assays

Five hundred YFP+Mac-1+Kit+ BM cells from AML mice
were plated in colony-forming unit (CFU) medium (M3534,
Stem Cell Technologies) for CFU-GM assays, according to
the manufacturer’s protocols [1, 18]. After 7 days, 2000 cells
from three dishes were isolated for secondary plating.
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Statistical analyses

Data are expressed as mean ± SEM. For all experiments
except determination of survival, data were analyzed by
Student’s t test and differences were considered statistically
significant if p < 0.05. The survival rates of the two groups
were analyzed using a log-rank test, and differences were
considered statistically significant if p < 0.05.

Results
CAMK activities are regulated by PirB signaling in AML
development

Because LILRBs are highly expressed by monocytic AML
(M5) cells [1], we used a retroviral MLL-AF9 transplantation mouse M5 AML model [19, 20] to investigate the
relationship between PirB signaling and CAMKs in AML
development. PirBTM mice [14], in which four exons
encoding the transmembrane domain and part of the
intracellular domain of PirB are deleted, were used to provide PirB-defective cells. PirBTM and control wild-type
(WT) cells infected with MSCV-MLL-AF9-IRES-YFP
retrovirus were transplanted to establish AML mice. We
sought to determine whether the CAMK family decreased
expression/activities in the PirB-defective MLL-AF9 AML
mouse model. Compared to WT controls, PirBTM cells
from MLL-AF9 AML mice had significantly decreased
phosphorylation of CAMKI, CAMKII, and CAMKIV (Sun
et al. [22]) (Fig. 1a), suggesting that CAMK activities are
regulated by the PirB signaling pathway.
To test whether CAMK activities are essential to AML
cells, we treated primary mouse MLL-AF9 AML cells
with the CAMKK inhibitor STO-609 and CAMK inhibitor
KN93. Both inhibitors diminished colonies in WT AML
cells instead of PirB-deficient AML cells (Fig. 1b, c). These
data show that the kinase activity of CAMK regulated by
PirB signaling is critical for the growth of AML cells.
CAMK transduction rescues PirB defects in AML

Patient overall survival analysis

Data were obtained from the TCGA AML database
(https://tcga-data.nci.nih.gov/docs/publications/tcga/;
accessed September 5, 2013), and levels were normalized
to GADPH expression. Patients were divided into two
groups based on whether their expression was above or
below the median level of a gene.
Western blotting

Cell lysates (100 μg samples) were separated by electrophoresis on a 4–12% SDS-polyacrylamide gel (BioRad),
and the proteins were transferred onto a nitrocellulose
membrane. The membrane was probed with indicated
primary antibody for 1 hour at room temperature and
then incubated with horseradish peroxidase-conjugated
secondary antibody, which was detected with the chemiluminescence SuperSignal kit (Pierce).

We used gain-of-function approaches to further determine
the role of CAMKI and CAMKIV in PirB signaling in AML
cells. We introduced retroviruses encoding CAMKI or
CAMKIV into PirB-defective AML cells to study whether
CAMKs could rescue PirB defects in AML development.
Mice transplanted with MLL-AF9-transduced PirBTM cells
developed AML more slowly and survived longer than those
transplanted with PirBTM cells that overexpressed CAMKI
or CAMKIV (Fig. 1d). The PirBTM leukemia cells that overexpress CAMK exhibited accelerated development as
demonstrated by the twofold increase in leukemia cell
infiltration in the peripheral blood. This was detected using
flow cytometry of these mice, compared to mice transplanted with PirBTM cells that did not overexpress CAMK,
at 28 days post-transplantation (Fig. 1e). The in vitro CFU
assay also showed both CAMKI and CAMKIV can increase PirBTM AML cells’ colony-forming ability (Fig. 1h).
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Fig. 1 Camk transduction enhances PirBTM MLL-AF9 AML development. a Phosphorylation of CAMKI, CAMKII, and CAMKIV was decreased in the
PirBTM MLL-AF9 AML BM cells compared to WT cells. b, c Colonies formed from WT or PirB TM AML cells upon CAMK or CAMKK inhibitor treatment.
Numbers of colonies formed by WT AML cells are decreased by addition of STO609 (STO) or KN93 (KN) (n = 3). d, e, h Retrovirally expressed Camk1
and Camk4, but not Camk1 mutant (K49E) or Camk4 mutant (K75M), rescued PIRB TM phenotype upon secondary transplantation. Retrovirally expressed
Camk1 and Camk4 had similar levels as endogenous proteins in WT controls (Additional file 1: Figure S1). d Survival curves of mice transplanted with 3000
of these ectopically Camk1-expressing, Camk4-expressing, Camk1 K49E-expressing, Camk4 K75M-expressing, or control cells (n = 15 mice). e Percentages of
retrovirus-infected (GFP+) AML cells in PB of secondary recipient mice after 28 days of transplantation. (n = 5 mice). h CFU numbers of retrovirus-infected
(GFP+) AML cells in colony-forming assays. The experiment was repeated three times with similar results. f, g, i Retrovirally expressed Camk1 and Camk4
cannot change WT AML phenotype upon second transplantation. f Survival curves of mice transplanted with 3000 WT AML cells of these ectopically
Camk1-expressing, Camk4-expressing, Camk1 K49E-expressing, Camk4 K75M-expressing, or control cells (n = 15 mice). g Percentages of retrovirus-infected
(GFP+) AML cells in PB of secondary recipient mice after 28 days of transplantation. (n = 5 mice). i CFU numbers of retrovirus-infected (GFP+) AML cells in
colony-forming assays. The experiment was repeated three times with similar results; *p < 0.05

Interestingly, in all of the rescue assays (Fig. 1d, e, h),
neither the kinase-inactive CAMKI mutant (K49E)
nor the CAMKIV mutant (K75M) was capable of
supporting PirBTM leukemia development. We also
performed the rescue assays in WT leukemia cells.
Though CAMK overexpression did not affect WT
leukemia development, the kinase-inactive CAMK1

mutant and CAMKIV mutant were able to play dormant negative roles in leukemia development in vivo
and in vitro (Fig. 1f, g, i). These results demonstrate
that CAMK, depending on their kinase activity, can
rescue PirB defects in AML development, supporting
our hypothesis that CAMKs are downstream mediators of PirB signaling.
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CAMKIV supports mouse AML development during serial
transplantation

To gain a deeper understanding of the mechanism by
which CAMKs support AML development, we sought to
examine AML development in genetic CAMK deletion
model. While CAMKI and CAMKII have multiple isoforms, CAMKIV exists as a single form. The availability
of the Camk4-null mice [10] allowed us to focus on the
role of CAMKIV as a representative of the CAMK family
in the mouse AML model. It is clear that PirB and
CAMKIV are highly expressed by hematopoietic progenitors and MLL-AF9 AML stem cell-enriched Mac-1+Kit+
population [11, 20, 21] (Additional file 1: Figure S2a-c).
The mice transplanted with MLL-AF9-transduced
Camk4-null cells developed AML significantly more
slowly than controls in both primary and secondary transplantation (Fig. 2a). The delayed development of the
Camk4-null AML was also evident from the significantly
decreased liver and spleen sizes and the numbers of white
blood cells in circulation in the mice transplanted with
Camk4-null cells compared to controls (Fig. 2b). The infiltration of Camk4-null myeloid leukemia cells into the liver
and spleen was significantly decreased (Fig. 2c). There
were more mature and differentiated hematopoietic cells
especially the Gr-1+ myeloid cells in mice that received
Camk4-null cells than in those given control WT cells,
based on cytospin and flow cytometry analyses (Fig. 2d–f).
These results demonstrated that a lack of CAMKIV
results in slower AML development.
We further analyzed whether CAMKIV affects AML
stem cell (AML-SC) activity. Primary transplants with
Camk4-null cells did not have significant differences in
YFP+Mac1+Kit+ cells from mice transplanted with WT
cells (Fig. 3a). In drastic contrast, the YFP+Mac1+Kit+
cells in secondarily transplanted mice decreased from 53
to 30% in BM and from 11 to 1% in peripheral blood
(Fig. 3b). A serial plating CFU assay was performed to
test the self-renewal of AML-SCs in vitro. The deficiency
of CAMKIV decreased CFUs in both primary plating
and secondary plating, with dramatically lower numbers
of colonies in secondary plating (Fig. 3c, d). Accordingly,
CAMKIV was capable of rescuing the defects of PirBTM
AML cells (Fig. 1h).
We also measured the apoptosis of Camk4-null and
control AML BM cells. Overall, the MLL-AF9 BM AML
cells had very low levels of early and late apoptosis (1.2
and 0.1%, Fig. 3e). Levels of apoptosis were dramatically
increased in the Camk4-null AML BM cells (4.6 and 0.9%,
Fig. 3e). These results suggest that CAMKIV supports the
survival of AML cells. This is consistent with the report
that CAMKIV is a critical survival factor for HSCs [10].
To quantitate how CAMKIV deficiency affects the
AML-SC frequency, we performed transplantations by
limiting dilution of sorted YFP+ WT and Camk4-null
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MLL-AF9 BM cells, collected from primary recipients.
Leukemia development, as measured by survival ratio and
latency days, is summarized in Fig. 3f. The frequency of
AML-SCs was assessed and plotted as the percentages of
non-leukemia-developing mice. Strikingly, the frequency
of functional AML-SCs in Camk4-null primary MLL-AF9
AML model mice was only 1/12 (= 24/295) of that in control WT AML mice. This limiting dilution transplantation
assay confirms that CAMKIV supports the activity of
AML-SCs.
CAMKs are essential for the growth of human leukemia
cells

Previously, we showed that the activation of LILRB2
induced CAMK activation. Similarly, based on our in silico
analysis of human samples, the expression of LILRB2 and
several CAMKs correlate inversely with the overall survival
of AML patients (Fig. 4a–d), and CAMK1 is highly
expressed by M5 AML cells (Fig. 4e) as LILRB2 [1]. These
results suggest that CAMKs may play important roles in
AML development. The activation of CAMKIV in human
myeloid cells including the monoblastic KASUMI-1 cells
and MLL-rearranged MV4-11 cells is greater than that in
lymphoblastic leukemia cells such as KASUMI-2 and
SUP-B15 cells (Additional file 1: Figure S3). The knockdown of CAMK1 or CAMK4 in AML cell lines including
MV4-11 cells and KASUMI-1 led to significant inhibition
of cell growth (Fig. 2g–j), indicating that CAMKs are functionally essential for human leukemia cells. By performing
rescue assays (Fig. 4k), and Crisper assays (Additional file1:
Figure S4) in MV4-11 cells, we proved the specific effect of
CAMKI deficiency on AML cell growth.
Next, we tested the in vivo effect of knockdown of
CAMK1 or CAMK4 expression in MV4-11 leukemia cells
in transplanted NOD/SCID-IL2RG (NSG) mice. Both
Camk1 or Camk4 knockdown significantly prolonged the
survival of xenografted mice (Fig. 5a) and greatly inhibited
leukemia development as determined by analysis of
knockdown cells (Fig. 5b), human leukemic hCD45+ cells
(Fig. 5c), and spleen size (Fig. 5d).
CREB mediates the effect of CAMKIV on AML

CREB was previously reported to be a possible downstream
target of CAMKIV [22]. We found that PirBTM AML cells
have decreased phosphorylation of both CAMKIV and
CREB (Fig. 1a, Fig. 6a). Therefore, we hypothesized that
CREB is a downstream mediator of PirB signaling in AML
cells. To test this hypothesis, we introduced retrovirally
expressed WT or inactive mutant CREB (S129A) into
PirBTM AML cells. WT but not S129A CREB could
rescue the defective phenotype of PirB TM AML cells
in vitro and in vivo (Fig. 6b–d). These results suggest
that CREB acts downstream of PirB-mediated signaling
to support AML development.
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Fig. 2 Loss of CAMKIV decreases MLL-AF9 AML development. a Mice transplanted with MLL-AF9-infected WT hematopoietic progenitors had significantly
reduced survival compared to mice transplanted with MLL-AF9-infected Camk4-null hematopoietic progenitors in both primary (p = 0.0019) and secondary
(p = 0.0021) transplantation (n = 16). b Comparison of the sizes of spleens and livers and numbers of peripheral blood cells of the mice transplanted with
WT MLL-AF9 cells and those with camk4-null MLL-AF9 cells at 41 days after first transplantation and 23 days after second transplantation. c Histological
analysis of AML infiltration in the livers of mice transplanted with control or CAMKIV-transduced PirBTM AML cells (hematoxylin/eosin staining). Significant
differences in AML infiltration to the liver in samples are indicated by arrows. d, e Representative Wright-Giemsa-stained cytospin preparation of the BM,
spleen, and peripheral blood cells from leukemic mice. f Representative flow cytometry plots show that camk4-null AML mice have more differentiated
cells in BM and peripheral blood (PB) compared to mice transplanted with WT cells, at 23 days after transplantation. *p < 0.05, scale bar is 100 μM

LILRB2 and CAMKs interact with each other in AML cells

To test the relationship between LILRB2 and CAMKs,
we transfected Flag-tagged LILRB2 and Myc-tagged
CAMKI or CAMKIV into 293T cells, then performed
co-immunoprecipitation and Western blotting assays.
Both CAMKI and CAMKIV bind LILRB2 in transfected

293T cells (Fig. 6e). Importantly, our bidirectional pulldown experiments showed that endogenous LILRB2 and
CAMK1 interact with each other in MV4-11 cells (Fig. 6f).
These data further support the conclusion that CAMKs
play a crucial role in LILRB2-mediated signaling in AML
cells (Fig. 6g).
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Fig. 3 Loss of CAMKIV decreases self-renewal capacity of AML-SCs. a, b Representative flow cytometry plots show that Camk4-null MLL-AF9 AML
mice had decreased numbers of YFP+Mac-1+Kit+ progenitors in both primary and secondary transplants. c, d Primary and secondary transplants
with Camk4-null MLL-AF9 BM cells show significantly decreased colony-forming ability (n = 3). e Camk4-null MLL-AF9 BM cells show increased
apoptosis. AnnexinV+/7AAD− indicates early apoptosis, and AnnexinV+/7AAD+ indicates late apoptosis. *p < 0.05. f Limiting dilution assays comparing
the frequencies of AML stem cells in WT and Camk4-null MLL-AF9 AML. The indicated YFP+ WT and Camk4-null MLL-AF9 BM cells that were collected
from primary recipients were co-transplanted with 2 × 105 bone marrow competitor cells into lethally irradiated recipients. The CRUs were calculated
by L-Calc software

Discussion
Recently, we showed that Angptl binding to human
LILRB2, or the mouse homolog PirB, stimulates phosphorylation of SHP-2 and CAMKIV [1, 2]. We sought to
understand how immune inhibitory receptors support
stem cell activity and cancer development. Here, we demonstrated that CAMKs play critical roles in sustaining
AML-SC activity and PirB supports AML development at

least partially through activation of CAMKs. To our
knowledge, this is the first demonstration of how an
ITIM-containing receptor signals, via activation of kinase
activities, to support cancer development.
The positive roles of CAMKs in mouse and human
leukemia development are supported by a variety of
evidence as shown in our study. (1) The expression of
CAMKs inversely correlates with the overall survival of
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 CAMKs play critical roles in human AML. a–d LILRB2 and CAMK expression negatively correlates with the overall survival of AML patients.
The mRNA expression data of LILRB2 and CAMKs were obtained from the TCGA AML database (https://tcga-data.nci.nih.gov/docs/publications/
tcga/; accessed November 5, 2012) and normalized by GADPH expression. Patients were separated into two groups based on whether they have
higher (n = 83) or lower (n = 82) than the average expression levels of the indicated genes (n = 186). e An in silico analysis of human Camk1
mRNA expression in 43 human AML samples as described previously [24]. f Treatment with shRNAs targeting Camk1 or Camk4 inhibited the
growth of MV4-11 cells. GFP+ cells were sorted by flow cytometry 1 day post-infection, and 20,000 cells were plated. Cell numbers were
determined at three time points (days 2, 4, and 6) from triplicate wells. The experiment was repeated three times with similar results. g Inhibition
of Camk1 or Camk4 expression inhibited the growth of KASUMI-1 cells. Cell numbers were determined at three time points (days 2, 4, and 6)
from triplicate wells. The experiment was repeated three times with similar results. Knockdown of Camk1 and Camk4 in MV4-11 cells and
KASUMI-1 cells as determined by Western blotting (h, i). k Rescue of Camk1-knockdown phenotype. Seven mutations were introduced into
puromycin-seleted Camk1 expression lentivirus vector. Expression from this mRNA did not change CAMK1 amino acid sequence and was not
silenced by shRNA Camk1. Mutant Camk1 (7 m) infected MV4-11 cells were resistant to the shRNA-Camk1-induced growth inhibition. The
experiment was repeated three times with similar results. GFP+ cells were sorted by flow cytometry 1 day post-infection, and 20,000 cells were
plated. Cell numbers were determined on days 2, 4, and 6 in triplicate wells. The experiment was repeated three times with similar results. l Western
blot showed mutant Camk1 could not be silenced by shRNA Camk1. m Cell growth of human AML cells (U937, Kasumi1 and MV4-11) were inhibited
upon CAMK (STO609) or CAMKK inhibitor (KN93) treatment. Numbers of cells were calculated 6 days post treatment; *p < 0.05

a

b

c

d

Fig. 5 Knockdown of CAMK1 or CAMK4 blocks xenograft of human leukemia cells. a Survival curve of NSG mice transplanted with MV4-11 cells (1 × 106
cells) infected with virus designed to express GFP and either scrambled shRNA, Camk1 shRNA, or Camk4 shRNA. GFP+ cells were collected and transplanted
into NSG mice 1 day post-infection (n = 10 mice). b Percentages of GFP+ cells in BM, spleen, liver, and PB at 28 days after transplantation. c Representative
flow cytometry plots indicating decreased spleen engraftment of MV4-11 cells treated with shRNA targeting Camk1 or Camk4. Staining with anti-human
CD45 antibodies confirmed engraftment was from transplanted human leukemia cells. The percentages of hCD45+ population are indicated. d Comparison
of the sizes of spleens of the mice transplanted with control MV4-11 leukemia cells or cells expressing shRNA targeting Camk1 or Camk4 (n = 5
mice); *p < 0.05
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e
f

g

Fig. 6 CREB activity plays important role in PirB/LILRB2-CAMKs signaling in AML-SCs. a Phosphorylation of CREB was decreased in the PirBTM
MLL-AF9 AML BM cells compared to control cells. b–d Retrovirally expressed Creb, but not Creb mutant (S129A), rescued PirBTM phenotype upon
secondary transplantation. Retrovirally expressed Creb had similar levels as endogenous proteins in WT controls. b Survival curves of mice transplanted
with 3000 of these ectopically Creb-expressing, Creb S129A-expressing, or control cells (n = 10 mice). c Percentages of retrovirus-infected (GFP+) AML
cells in PB of secondary recipient mice after 28 days of transplantation. (n = 5 mice). d CFU numbers of retrovirus-infected (GFP+) AML cells in colony-forming
assays. The experiment was repeated three times with similar results; e CAMKI and LILRB2 bound in transfected 293T cells. The indicated flag-tagged LILRB2
or myc-tagged CAMKI or CAMKIV proteins were overexpressed in 293 cells. Flag antibody was used to precipitate LILRB2 proteins, and the flag or myc
antibodies were used in Western blots. f Endogenous CAMKI and LILRB2 interact with each other as determined by bidirectional pull-down assays.
MV4-11 cells (1 × 107 cells) were lysed with transmembrane protein extraction reagent and indicated antibodies were used for immunoprecipitation
and Western blot; *p < 0.05. g Schematic summary of the signaling pathway mediated by the PirB/LILRB2-CAMKs-CREB in AML cells

AML patients. (2) Knockdown of CAMKI or CAMKIV
inhibits growth of human AML cells in vitro and in vivo.
(3) CAMKI and CAMKIV rescue PirB deficiency in a
mouse AML model, and deletion of CAMKIV decreased

the activity of AML-SCs. (4) CAMKIV supports the development of acute lymphoblastic leukemia in a mouse
model (unpublished data). These results are in agreement with the previous reports that CAMKIV is
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required for HSC activity and CAMKII suppresses
differentiation and stimulates proliferation of myeloid
leukemia cells [10]. Because we used the MLL-AF9
fusion oncogene to initiate AML in the mouse model,
our results suggest that CAMKs play a critical role in
the maintenance and progression of AML.
Because CAMKs network with many different signaling pathways, and the signaling of ITAM or ITIM
receptors is rather divergent [23], it is possible that
CAMKs only represent a critical branch of the total
signaling cascades linked to LILRB2/PirB. In general
SHP-1 and SHP-2 act immediately downstream of an
ITIM-containing inhibitory receptor such as LILRB2/
PirB to initiate further signaling to regulate cell fates.
While we showed that SHP-1/2 can induce CAMK
activation in AML cells [1, 11], it will be important
to determine whether other signaling molecules act
downstream of LILRB/SHP in leukemia cells. In
addition, although we can use serial transplantation
to measure AML-SC function and self-renewal,
because AML-SCs were not purified to homogeneity
in our study, it remains to be determined whether
this signaling network differs in stem cells and in
more differentiated AML cells.

Conclusion
We demonstrated that CAMKs are important signaling molecules to support self-renewal and survival in
AML cells. Our results thus revealed one mechanism
by which the ITIM-containing inhibitory receptors
support stem cell activity and AML development and
also have important implications in development of
new therapeutic strategies in leukemia treatment. It is
known that deletion of PirB from normal
hematopoiesis or adult HSCs does not have significant
in vivo effects [1], and Camk4-knockout mice had only
minor defects in HSCs [10]. By contrast, the loss of
function of LILRB2/PirB or CAMKs are detrimental to
AML development. It is therefore likely that inhibition
of CAMKs will be effective in treating leukemia with
minimal side effects in the hematopoietic system.
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